Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

PHG vs BAX vs SYK vs BDX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
PHG
Koninklijke Philips N.V.

Medical - Devices

HealthcareNYSE • NL
Market Cap$25.84B
5Y Perf.-34.1%
BAX
Baxter International Inc.

Medical - Instruments & Supplies

HealthcareNYSE • US
Market Cap$9.04B
5Y Perf.-80.5%
SYK
Stryker Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$112.69B
5Y Perf.+50.3%
BDX
Becton, Dickinson and Company

Medical - Instruments & Supplies

HealthcareNYSE • US
Market Cap$55.53B
5Y Perf.+3.0%

PHG vs BAX vs SYK vs BDX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
PHG logoPHG
BAX logoBAX
SYK logoSYK
BDX logoBDX
IndustryMedical - DevicesMedical - Instruments & SuppliesMedical - DevicesMedical - Instruments & Supplies
Market Cap$25.84B$9.04B$112.69B$55.53B
Revenue (TTM)$17.83B$11.32B$25.12B$21.36B
Net Income (TTM)$895M$-1.10B$3.25B$1.14B
Gross Margin45.2%30.1%63.5%46.5%
Operating Margin8.0%-2.7%22.4%10.6%
Forward P/E17.5x9.2x19.6x12.3x
Total Debt$8.09B$10.00B$14.86B$19.18B
Cash & Equiv.$2.79B$1.97B$4.01B$851M

PHG vs BAX vs SYK vs BDXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

PHG
BAX
SYK
BDX
StockMay 20May 26Return
Koninklijke Philips… (PHG)10065.9-34.1%
Baxter Internationa… (BAX)10019.5-80.5%
Stryker Corporation (SYK)100150.3+50.3%
Becton, Dickinson a… (BDX)100103.0+3.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: PHG vs BAX vs SYK vs BDX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: SYK leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Becton, Dickinson and Company is the stronger pick specifically for valuation and capital efficiency and recent price momentum and sentiment. BAX also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
PHG
Koninklijke Philips N.V.
The Quality Angle

PHG lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
BAX
Baxter International Inc.
The Defensive Pick

BAX is the clearest fit if your priority is defensive.

  • Beta 1.37, yield 3.9%, current ratio 2.31x
  • 3.9% yield, vs SYK's 1.1%
Best for: defensive
SYK
Stryker Corporation
The Income Pick

SYK carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 34 yrs, beta 0.55, yield 1.1%
  • Rev growth 11.2%, EPS growth 8.2%, 3Y rev CAGR 10.8%
  • 187.1% 10Y total return vs BDX's 80.2%
  • Lower volatility, beta 0.55, Low D/E 66.3%, current ratio 1.89x
Best for: income & stability and growth exposure
BDX
Becton, Dickinson and Company
The Value Pick

BDX is the #2 pick in this set and the best alternative if valuation efficiency is your priority.

  • PEG 0.74 vs SYK's 1.32
  • Lower P/E (12.3x vs 19.6x), PEG 0.74 vs 1.32
  • +51.8% vs BAX's -41.8%
Best for: valuation efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthSYK logoSYK11.2% revenue growth vs PHG's -1.0%
ValueBDX logoBDXLower P/E (12.3x vs 19.6x), PEG 0.74 vs 1.32
Quality / MarginsSYK logoSYK12.9% margin vs BAX's -9.7%
Stability / SafetySYK logoSYKBeta 0.55 vs BAX's 1.37, lower leverage
DividendsBAX logoBAX3.9% yield, vs SYK's 1.1%
Momentum (1Y)BDX logoBDX+51.8% vs BAX's -41.8%
Efficiency (ROA)SYK logoSYK6.9% ROA vs BAX's -5.4%, ROIC 11.4% vs -1.4%

PHG vs BAX vs SYK vs BDX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

PHGKoninklijke Philips N.V.

Segment breakdown not available.

BAXBaxter International Inc.
FY 2025
Medical Products And Therapies
48.8%$5.3B
Healthcare Systems and Technologies
28.3%$3.1B
Pharmaceuticals
22.9%$2.5B
SYKStryker Corporation
FY 2025
MedSurg
62.3%$15.6B
Orthopaedics
37.7%$9.5B
BDXBecton, Dickinson and Company
FY 2025
Medical
52.5%$11.5B
Interventional
23.9%$5.2B
Life Sciences
23.7%$5.2B

PHG vs BAX vs SYK vs BDX — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLSYKLAGGINGBDX

Income & Cash Flow (Last 12 Months)

SYK leads this category, winning 5 of 6 comparable metrics.

SYK is the larger business by revenue, generating $25.1B annually — 2.2x BAX's $11.3B. SYK is the more profitable business, keeping 12.9% of every revenue dollar as net income compared to BAX's -9.7%. On growth, SYK holds the edge at +11.4% YoY revenue growth, suggesting stronger near-term business momentum.

MetricPHG logoPHGKoninklijke Phili…BAX logoBAXBaxter Internatio…SYK logoSYKStryker Corporati…BDX logoBDXBecton, Dickinson…
RevenueTrailing 12 months$17.8B$11.3B$25.1B$21.4B
EBITDAEarnings before interest/tax$2.5B$671M$6.3B$4.2B
Net IncomeAfter-tax profit$895M-$1.1B$3.2B$1.1B
Free Cash FlowCash after capex$755M$501M$4.3B$3.1B
Gross MarginGross profit ÷ Revenue+45.2%+30.1%+63.5%+46.5%
Operating MarginEBIT ÷ Revenue+8.0%-2.7%+22.4%+10.6%
Net MarginNet income ÷ Revenue+5.0%-9.7%+12.9%+5.3%
FCF MarginFCF ÷ Revenue+4.2%+4.4%+17.1%+14.7%
Rev. Growth (YoY)Latest quarter vs prior year+1.1%+2.9%+11.4%-10.6%
EPS Growth (YoY)Latest quarter vs prior year+2.1%-112.0%+56.0%-2.0%
SYK leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

BAX leads this category, winning 4 of 7 comparable metrics.

At 24.9x trailing earnings, PHG trades at a 29% valuation discount to SYK's 35.0x P/E. Adjusting for growth (PEG ratio), BDX offers better value at 1.59x vs SYK's 2.36x — a lower PEG means you pay less per unit of expected earnings growth.

MetricPHG logoPHGKoninklijke Phili…BAX logoBAXBaxter Internatio…SYK logoSYKStryker Corporati…BDX logoBDXBecton, Dickinson…
Market CapShares × price$25.8B$9.0B$112.7B$55.5B
Enterprise ValueMkt cap + debt − cash$32.1B$17.1B$123.5B$73.9B
Trailing P/EPrice ÷ TTM EPS24.85x-10.01x35.03x26.29x
Forward P/EPrice ÷ next-FY EPS est.17.55x9.17x19.62x12.27x
PEG RatioP/E ÷ EPS growth rate2.36x1.59x
EV / EBITDAEnterprise value multiple10.70x25.37x20.31x14.65x
Price / SalesMarket cap ÷ Revenue1.23x0.80x4.49x2.54x
Price / BookPrice ÷ Book value/share2.02x1.47x5.02x1.73x
Price / FCFMarket cap ÷ FCF24.62x27.99x26.31x20.80x
BAX leads this category, winning 4 of 7 comparable metrics.

Profitability & Efficiency

SYK leads this category, winning 6 of 9 comparable metrics.

SYK delivers a 15.0% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $-16 for BAX. SYK carries lower financial leverage with a 0.66x debt-to-equity ratio, signaling a more conservative balance sheet compared to BAX's 1.64x. On the Piotroski fundamental quality scale (0–9), PHG scores 7/9 vs BAX's 5/9, reflecting strong financial health.

MetricPHG logoPHGKoninklijke Phili…BAX logoBAXBaxter Internatio…SYK logoSYKStryker Corporati…BDX logoBDXBecton, Dickinson…
ROE (TTM)Return on equity+8.2%-16.5%+15.0%+4.5%
ROA (TTM)Return on assets+3.4%-5.4%+6.9%+2.1%
ROICReturn on invested capital+6.4%-1.4%+11.4%+4.3%
ROCEReturn on capital employed+7.1%-1.7%+13.0%+5.4%
Piotroski ScoreFundamental quality 0–97567
Debt / EquityFinancial leverage0.74x1.64x0.66x0.76x
Net DebtTotal debt minus cash$5.3B$8.0B$10.8B$18.3B
Cash & Equiv.Liquid assets$2.8B$2.0B$4.0B$851M
Total DebtShort + long-term debt$8.1B$10.0B$14.9B$19.2B
Interest CoverageEBIT ÷ Interest expense4.34x-0.83x6.72x4.09x
SYK leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — PHG and SYK and BDX each lead in 2 of 6 comparable metrics.

A $10,000 investment in SYK five years ago would be worth $12,152 today (with dividends reinvested), compared to $2,566 for BAX. Over the past 12 months, BDX leads with a +51.8% total return vs BAX's -41.8%. The 3-year compound annual growth rate (CAGR) favors PHG at 11.6% vs BAX's -24.1% — a key indicator of consistent wealth creation.

MetricPHG logoPHGKoninklijke Phili…BAX logoBAXBaxter Internatio…SYK logoSYKStryker Corporati…BDX logoBDXBecton, Dickinson…
YTD ReturnYear-to-date+0.3%-10.2%-15.2%+0.7%
1-Year ReturnPast 12 months+17.7%-41.8%-22.5%+51.8%
3-Year ReturnCumulative with dividends+38.8%-56.3%+5.5%+5.0%
5-Year ReturnCumulative with dividends-42.7%-74.3%+21.5%+16.9%
10-Year ReturnCumulative with dividends+48.3%-42.4%+187.1%+80.2%
CAGR (3Y)Annualised 3-year return+11.6%-24.1%+1.8%+1.6%
Evenly matched — PHG and SYK and BDX each lead in 2 of 6 comparable metrics.

Risk & Volatility

Evenly matched — PHG and SYK each lead in 1 of 2 comparable metrics.

SYK is the less volatile stock with a 0.55 beta — it tends to amplify market swings less than BAX's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PHG currently trades 81.2% from its 52-week high vs BAX's 53.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricPHG logoPHGKoninklijke Phili…BAX logoBAXBaxter Internatio…SYK logoSYKStryker Corporati…BDX logoBDXBecton, Dickinson…
Beta (5Y)Sensitivity to S&P 5001.12x1.37x0.55x0.66x
52-Week HighHighest price in past year$33.44$32.68$404.87$205.52
52-Week LowLowest price in past year$21.95$15.73$289.91$100.31
% of 52W HighCurrent price vs 52-week peak+81.2%+53.6%+72.7%+74.6%
RSI (14)Momentum oscillator 0–10047.744.024.332.2
Avg Volume (50D)Average daily shares traded1.0M8.7M2.1M2.5M
Evenly matched — PHG and SYK each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — BAX and SYK each lead in 1 of 2 comparable metrics.

Analyst consensus: PHG as "Hold", BAX as "Hold", SYK as "Buy", BDX as "Buy". Consensus price targets imply 37.2% upside for SYK (target: $404) vs 12.8% for BDX (target: $173). For income investors, BAX offers the higher dividend yield at 3.87% vs SYK's 1.14%.

MetricPHG logoPHGKoninklijke Phili…BAX logoBAXBaxter Internatio…SYK logoSYKStryker Corporati…BDX logoBDXBecton, Dickinson…
Analyst RatingConsensus buy/hold/sellHoldHoldBuyBuy
Price TargetConsensus 12-month target$19.75$403.69$172.85
# AnalystsCovering analysts22365033
Dividend YieldAnnual dividend ÷ price+1.5%+3.9%+1.1%+2.7%
Dividend StreakConsecutive years of raises10341
Dividend / ShareAnnual DPS$0.34$0.68$3.36$4.17
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%+1.8%
Evenly matched — BAX and SYK each lead in 1 of 2 comparable metrics.
Key Takeaway

SYK leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). BAX leads in 1 (Valuation Metrics). 3 tied.

Best OverallStryker Corporation (SYK)Leads 2 of 6 categories
Loading custom metrics...

PHG vs BAX vs SYK vs BDX: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is PHG or BAX or SYK or BDX a better buy right now?

For growth investors, Stryker Corporation (SYK) is the stronger pick with 11.

2% revenue growth year-over-year, versus -1. 0% for Koninklijke Philips N. V. (PHG). Koninklijke Philips N. V. (PHG) offers the better valuation at 24. 9x trailing P/E (17. 5x forward), making it the more compelling value choice. Analysts rate Stryker Corporation (SYK) a "Buy" — based on 50 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — PHG or BAX or SYK or BDX?

On trailing P/E, Koninklijke Philips N.

V. (PHG) is the cheapest at 24. 9x versus Stryker Corporation at 35. 0x. On forward P/E, Baxter International Inc. is actually cheaper at 9. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Becton, Dickinson and Company wins at 0. 74x versus Stryker Corporation's 1. 32x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — PHG or BAX or SYK or BDX?

Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +21.

5%, compared to -74. 3% for Baxter International Inc. (BAX). Over 10 years, the gap is even starker: SYK returned +187. 1% versus BAX's -42. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — PHG or BAX or SYK or BDX?

By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.

55β versus Baxter International Inc. 's 1. 37β — meaning BAX is approximately 151% more volatile than SYK relative to the S&P 500. On balance sheet safety, Stryker Corporation (SYK) carries a lower debt/equity ratio of 66% versus 164% for Baxter International Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — PHG or BAX or SYK or BDX?

By revenue growth (latest reported year), Stryker Corporation (SYK) is pulling ahead at 11.

2% versus -1. 0% for Koninklijke Philips N. V. (PHG). On earnings-per-share growth, the picture is similar: Koninklijke Philips N. V. grew EPS 224. 0% year-over-year, compared to -37. 8% for Baxter International Inc.. Over a 3-year CAGR, SYK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — PHG or BAX or SYK or BDX?

Stryker Corporation (SYK) is the more profitable company, earning 12.

9% net margin versus -8. 5% for Baxter International Inc. — meaning it keeps 12. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SYK leads at 19. 5% versus -2. 7% for BAX. At the gross margin level — before operating expenses — SYK leads at 64. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is PHG or BAX or SYK or BDX more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Becton, Dickinson and Company (BDX) is the more undervalued stock at a PEG of 0. 74x versus Stryker Corporation's 1. 32x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Baxter International Inc. (BAX) trades at 9. 2x forward P/E versus 19. 6x for Stryker Corporation — 10. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SYK: 37. 2% to $403. 69.

08

Which pays a better dividend — PHG or BAX or SYK or BDX?

All stocks in this comparison pay dividends.

Baxter International Inc. (BAX) offers the highest yield at 3. 9%, versus 1. 1% for Stryker Corporation (SYK).

09

Is PHG or BAX or SYK or BDX better for a retirement portfolio?

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

55), 1. 1% yield, +187. 1% 10Y return). Both have compounded well over 10 years (SYK: +187. 1%, BAX: -42. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between PHG and BAX and SYK and BDX?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PHG is a mid-cap quality compounder stock; BAX is a small-cap income-oriented stock; SYK is a mid-cap quality compounder stock; BDX is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

PHG

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

BAX

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 18%
  • Dividend Yield > 1.5%
Run This Screen
Stocks Like

SYK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen
Stocks Like

BDX

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
  • Dividend Yield > 1.0%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform PHG and BAX and SYK and BDX on the metrics below

Revenue Growth>
%
(PHG: 1.1% · BAX: 2.9%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.